Design and Synthesis of Fluorescent Methylphenidate Analogues for a FRET‐Based Assay of Synapsin III Binding
- 16 June 2020
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 15 (14) , 1330-1337
Abstract
We previously described synapsin III (Syn III) as a synaptic phosphoprotein that controls dopamine release in cooperation with α‐synuclein (aSyn). Moreover, we found that in Parkinson's disease (PD), Syn III also participates in aSyn aggregation and toxicity. Our recent observations point to threo‐methylphenidate (MPH), a monoamine re‐uptake inhibitor that efficiently counteracts the freezing‐gait characteristic of advanced PD, as a ligand for Syn III. We have designed and synthesised two different fluorescently labelled MPH derivatives, one with Rhodamine Red (RHOD) and one with 5‐carboxytetramethylrhodamine (TAMRA), to be used for assessing MPH binding to Syn III by FRET. TAMRA‐MPH exhibited the ideal characteristics to be used as a FRET acceptor, as it was able to enter into the SK‐N‐SH cells and could interact specifically with human green fluorescent protein (GFP)‐tagged Syn III but not with GFP alone. Moreover, the uptake of TAMRA‐MPH and co‐localization with Syn III was also observed in primary mesencephalic neurons. These findings support that MPH is a Syn III ligand and that TAMRA‐conjugated drug molecules might be valuable tools to study drug‐ligand interactions by FRET or to detect Syn III in cytological and histological samples.Keywords
Funding Information
- Università degli Studi di Brescia (Z1A DA000610)
This publication has 26 references indexed in Scilit:
- Association of Synapsin III Gene with Adult Attention Deficit Hyperactivity DisorderDNA and Cell Biology, 2013
- From α-synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's diseaseBrain Research, 2012
- Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trialThe Lancet Neurology, 2012
- Synapsin III: Role in neuronal plasticity and diseaseSeminars in Cell & Developmental Biology, 2011
- Synapsins Differentially Control Dopamine and Serotonin ReleaseJournal of Neuroscience, 2010
- Parkinson's Disease-Related Protein, α-Synuclein, in Malignant MelanomaPLOS ONE, 2010
- Alpha‐synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activationJournal of Neurochemistry, 2008
- Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Absence of synapsin I and II is accompanied by decreases in vesicular transport of specific neurotransmittersJournal of Neurochemistry, 2006
- Expression of synapsin III in nerve terminals and neurogenic regions of the adult brainJournal of Comparative Neurology, 2002